Central Miami Medical Institute | Miami, FL

Research site

(Unclaimed)

Location

719 NW 13th Ave, Miami, Florida, United States of America

Site insights

Top conditions

Top treatments

Troriluzole

Simufilam

ACP-204

SEP-363856

Semaglutide

SEP-4199

Psilocybin

KarXT

Semagludtide

AVP-786

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

6 of 16 total trials

A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression (RECOVER)

Objectives of this study are to determine whether active VNS Therapy treatment is superior to a no stimulation control in producing a reduction in ba...

Enrolling

Treatment Resistant Depression

Device: Vagus Nerve Stimulation (VNS)

A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression) (X-CEED)

X-CEED is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of azetukalner in adult part...

Enrolling

Bipolar II Disorder

Bipolar I Disorder

Drug: Placebo

Drug: Azetukalner

ACP-204 in Adults With Alzheimer's Disease Psychosis

This is a master protocol for 3 independent, seamlessly enrolling, multicenter, randomized, double-blind, placebo-controlled, parallel-group studies...

Enrolling

Alzheimer's Disease Psychosis

Drug: Placebo

Drug: ACP-204

Clinical Trial on Agitation in Alzheimer's Dementia (CALMA)

The purpose of this study is to assess the efficacy of the oral medication IGC-AD1, a THC-based (Delta-9-Tetrahydrocannabinol) formulation administer...

Enrolling

NPS

Alzheimer Disease

Drug: IGC-AD1-Placebo

Drug: IGC-AD1-Active

Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD

Efficacy, Safety, and Tolerability of two administrations of COMP360 in participants with treatment-resistant depression (TRD)

Active, not recruiting

Treatment Resistant Depression

Drug: Psilocybin

Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type

This study will be conducted to evaluate the efficacy, safety, tolerability, and pharmacokinetics of masupirdine compared to placebo for the treatmen...

Enrolling

Agitation

Alzheimer's Type Dementia

Drug: Masupirdine 100 mg

Drug: Placebo